881 research outputs found

    Embeddability for Three-Dimensional Cauchy-Riemann Manifolds and CR Yamabe Invariants

    Full text link
    Let M^3 be a closed CR 3-manifold. In this paper we derive a Bochner formula for the Kohn Laplacian in which the pseudo-hermitian torsion plays no role. By means of this formula we show that the non-zero eigenvalues of the Kohn Laplacian are bounded below by a positive constant provided the CR Paneitz operator is non-negative and the Webster curvature is positive. Our lower bound for the non-zero eigenvalues is sharp and is attained on S^3. A consequence of our lower bound is that all compact CR 3-manifolds with non-negative CR Paneitz operator and positive CR Yamabe constant are embeddable. Non-negativity of the CR Paneitz operator and positivity of the CR Yamabe constant are both CR invariant conditions and do not depend on conformal changes of the contact form. In addition we show that under the sufficient conditions above for embeddability, the embedding is stable in the sense of Burns and Epstein. We also show that for the Rossi example for non-embedability, the CR Paneitz operator is negative. For CR structures close to the standard structure on S3S^3 we show the CR Paneitz operator is positive on the space of pluriharmonic functions with respect to the standard CR structure on S3S^3.Comment: The new version also proves a partial converse. That is for CR structures close to the standard CR structure on the 3-sphere, embedabillity is shown to imply the non-negativity of the CR Paneitz operator on pluriharmonic functions for the standard CR structure. Typos are corrected, and statement of prop. 1.11 revise

    Umbilic hypersurfaces of constant sigma-k curvature in the Heisenberg group

    Full text link
    We study immersed, connected, umbilic hypersurfaces in the Heisenberg group HnH_{n} with nn ≥\geq 2.2. We show that such a hypersurface, if closed, must be rotationally invariant up to a Heisenberg translation. Moreover, we prove that, among others, Pansu spheres are the only such spheres with positive constant sigma-k curvature up to Heisenberg translations.Comment: 28 pages, 6 figure

    Synergistic effect of imp/ostA and msbA in hydrophobic drug resistance of Helicobacter pylori

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Contamination of endoscopy equipment by <it>Helicobacter pylori </it>(<it>H. pylori</it>) frequently occurs after endoscopic examination of <it>H. pylori</it>-infected patients. In the hospital, manual pre-cleaning and soaking in glutaraldehyde is an important process to disinfect endoscopes. However, this might not be sufficient to remove <it>H. pylori </it>completely, and some glutaraldehyde-resistant bacteria might survive and be passed to the next patient undergoing endoscopic examination through unidentified mechanisms. We identified an Imp/OstA protein associated with glutaraldehyde resistance in a clinical strain, NTUH-C1, from our previous study. To better understand and manage the problem of glutaraldehyde resistance, we further investigated its mechanism.</p> <p>Results</p> <p>The minimal inhibitory concentrations (MICs) of glutaraldehyde andexpression of <it>imp/ostA </it>RNA in 11 clinical isolates from the National Taiwan University Hospital were determined. After glutaraldehyde treatment, RNA expression in the strains with the MICs of 4–10 μg/ml was higher than that in strains with the MICs of 1–3 μg/ml. We examined the full-genome expression of strain NTUH-S1 after glutaraldehyde treatment using a microarray and found that 40 genes were upregulated and 31 genes were downregulated. Among the upregulated genes, <it>imp/ostA </it>and <it>msbA</it>, two putative lipopolysaccharide biogenesis genes, were selected for further characterization. The sensitivity to glutaraldehyde or hydrophobic drugs increased in both of <it>imp/ostA </it>and <it>msbA </it>single mutants. The <it>imp/ostA </it>and <it>msbA </it>double mutant was also hypersensitive to these chemicals. The lipopolysaccharide contents decreased in individual <it>imp/ostA </it>and <it>msbA </it>mutants and dramatically reduced in the <it>imp/ostA </it>and <it>msbA </it>double mutant. Outer membrane permeability assay demonstrated that the <it>imp/ostA </it>and <it>msbA </it>double mutation resulted in the increase of outer membrane permeability. Ethidium bromide accumulation assay demonstrated that MsbA was involved in efflux of hydrophobic drugs.</p> <p>Conclusion</p> <p>The expression levels of <it>imp/ostA </it>and <it>msbA </it>were correlated with glutaraldehyde resistance in clinical isolates after glutaraldehyde treatment. Imp/OstA and MsbA play a synergistic role in hydrophobic drugs resistance and lipopolysaccharide biogenesis in <it>H. pylori</it>.</p

    Hedyotis diffusa

    Get PDF
    Traditional Chinese medicine (TCM), which is the most common type of complementary and alternative medicine (CAM) used in Taiwan, is increasingly used to treat patients with breast cancer. However, large-scale studies on the patterns of TCM prescriptions for breast cancer are still lacking. The aim of this study was to determine the core treatment of TCM prescriptions used for breast cancer recorded in the Taiwan National Health Insurance Research Database. TCM visits made for breast cancer in 2008 were identified using ICD-9 codes. The prescriptions obtained at these TCM visits were evaluated using association rule mining to evaluate the combinations of Chinese herbal medicine (CHM) used to treat breast cancer patients. A total of 37,176 prescriptions were made for 4,436 outpatients with breast cancer. Association rule mining and network analysis identified Hedyotis diffusa plus Scutellaria barbata as the most common duplex medicinal (10.9%) used for the core treatment of breast cancer. Jia-Wei-Xiao-Yao-San (19.6%) and Hedyotis diffusa (41.9%) were the most commonly prescribed herbal formula (HF) and single herb (SH), respectively. Only 35% of the commonly used CHM had been studied for efficacy. More clinical trials are needed to evaluate the efficacy and safety of these CHM used to treat breast cancer
    • …
    corecore